tetano
Editor, Senior Moderator
Br J Haematol
. 2021 Jun 3.
doi: 10.1111/bjh.17568. Online ahead of print.
Single dose of BNT162b2 mRNA vaccine against severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) induces neutralising antibody and polyfunctional T-cell responses in patients with chronic myeloid leukaemia
Patrick Harrington[SUP] 1 2 [/SUP], Katie J Doores[SUP] 3 [/SUP], Deepti Radia[SUP] 1 [/SUP], Amy O'Reilly[SUP] 1 [/SUP], Ho Pui Jeff Lam[SUP] 1 [/SUP], Jeffrey Seow[SUP] 3 [/SUP], Carl Graham[SUP] 3 [/SUP], Thomas Lechmere[SUP] 3 [/SUP], Donal McLornan[SUP] 1 2 [/SUP], Richard Dillon[SUP] 1 4 [/SUP], Yogita Shanmugharaj[SUP] 1 [/SUP], Andreas Espehana[SUP] 1 [/SUP], Claire Woodley[SUP] 1 [/SUP], Jamie Saunders[SUP] 1 [/SUP], Natalia Curto-Garcia[SUP] 1 [/SUP], Jennifer O'Sullivan[SUP] 1 [/SUP], Kavita Raj[SUP] 1 [/SUP], Shahram Kordasti[SUP] 1 2 [/SUP], Michael H Malim[SUP] 3 [/SUP], Claire Harrison[SUP] 1 2 [/SUP], Hugues de Lavallade[SUP] 1 2 5 [/SUP]
Affiliations
Abstract
Patients receiving targeted cancer treatments such as tyrosine kinase inhibitors (TKIs) have been classified in the clinically extremely vulnerable group to develop severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), including patients with chronic myeloid leukaemia (CML) taking TKIs. In addition, concerns that immunocompromised individuals with solid and haematological malignancies may not mount an adequate immune response to a single dose of SARS-CoV-2 BNT162b2 (Pfizer-BioNTech) vaccine have been raised. In the present study, we evaluated humoral and cellular immune responses after a first injection of BNT162b2 vaccine in 16 patients with CML. Seroconversion and cellular immune response before and after vaccination were assessed. By day 21 after vaccination, anti-Spike immunoglobulin G was detected in 14/16 (87·5%) of the patients with CML and all developed a neutralising antibody response [serum dilution that inhibits 50% infection (ID[SUB]50[/SUB] ) >50], including medium (ID[SUB]50[/SUB] of 200-500) or high (ID[SUB]50[/SUB] of 501-2000) neutralising antibodies titres in nine of the 16 (56·25%) patients. T-cell response was seen in 14/15 (93·3%) evaluable patients, with polyfunctional responses seen in 12/15 (80%) patients (polyfunctional CD4[SUP]+[/SUP] response nine of 15, polyfunctional CD8[SUP]+[/SUP] T-cell response nine of 15). These data demonstrate the immunogenicity of a single dose of SARS-CoV-2 BNT162b2 vaccine in most patients with CML, with both neutralising antibodies and polyfunctional T-cell responses seen in contrast to patients with solid tumour or lymphoid haematological malignancies.
Keywords: BNT162b2 vaccine; SARS-CoV2 vaccine; chronic myeloid leukaemia; tyrosine kinase inhibitor.
. 2021 Jun 3.
doi: 10.1111/bjh.17568. Online ahead of print.
Single dose of BNT162b2 mRNA vaccine against severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) induces neutralising antibody and polyfunctional T-cell responses in patients with chronic myeloid leukaemia
Patrick Harrington[SUP] 1 2 [/SUP], Katie J Doores[SUP] 3 [/SUP], Deepti Radia[SUP] 1 [/SUP], Amy O'Reilly[SUP] 1 [/SUP], Ho Pui Jeff Lam[SUP] 1 [/SUP], Jeffrey Seow[SUP] 3 [/SUP], Carl Graham[SUP] 3 [/SUP], Thomas Lechmere[SUP] 3 [/SUP], Donal McLornan[SUP] 1 2 [/SUP], Richard Dillon[SUP] 1 4 [/SUP], Yogita Shanmugharaj[SUP] 1 [/SUP], Andreas Espehana[SUP] 1 [/SUP], Claire Woodley[SUP] 1 [/SUP], Jamie Saunders[SUP] 1 [/SUP], Natalia Curto-Garcia[SUP] 1 [/SUP], Jennifer O'Sullivan[SUP] 1 [/SUP], Kavita Raj[SUP] 1 [/SUP], Shahram Kordasti[SUP] 1 2 [/SUP], Michael H Malim[SUP] 3 [/SUP], Claire Harrison[SUP] 1 2 [/SUP], Hugues de Lavallade[SUP] 1 2 5 [/SUP]
Affiliations
- PMID: 34085278
- DOI: 10.1111/bjh.17568
Abstract
Patients receiving targeted cancer treatments such as tyrosine kinase inhibitors (TKIs) have been classified in the clinically extremely vulnerable group to develop severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), including patients with chronic myeloid leukaemia (CML) taking TKIs. In addition, concerns that immunocompromised individuals with solid and haematological malignancies may not mount an adequate immune response to a single dose of SARS-CoV-2 BNT162b2 (Pfizer-BioNTech) vaccine have been raised. In the present study, we evaluated humoral and cellular immune responses after a first injection of BNT162b2 vaccine in 16 patients with CML. Seroconversion and cellular immune response before and after vaccination were assessed. By day 21 after vaccination, anti-Spike immunoglobulin G was detected in 14/16 (87·5%) of the patients with CML and all developed a neutralising antibody response [serum dilution that inhibits 50% infection (ID[SUB]50[/SUB] ) >50], including medium (ID[SUB]50[/SUB] of 200-500) or high (ID[SUB]50[/SUB] of 501-2000) neutralising antibodies titres in nine of the 16 (56·25%) patients. T-cell response was seen in 14/15 (93·3%) evaluable patients, with polyfunctional responses seen in 12/15 (80%) patients (polyfunctional CD4[SUP]+[/SUP] response nine of 15, polyfunctional CD8[SUP]+[/SUP] T-cell response nine of 15). These data demonstrate the immunogenicity of a single dose of SARS-CoV-2 BNT162b2 vaccine in most patients with CML, with both neutralising antibodies and polyfunctional T-cell responses seen in contrast to patients with solid tumour or lymphoid haematological malignancies.
Keywords: BNT162b2 vaccine; SARS-CoV2 vaccine; chronic myeloid leukaemia; tyrosine kinase inhibitor.